Publications by authors named "James Witek"

Claim this Profile
L
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.
Abbie Oey, Matthew McClure, Julian A Symons, Sushmita Chanda, John Fry, James Witek

PLoS One· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza.
Wilbert van Duijnhoven, Ilse Van Dromme, Steven Haesendonckx, James Witek, Lorant Leopold

Contemp Clin Trials· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS).
Yannick Vandendijck, Jane Scott, Dirk Heerwegh, Wim Van Der Elst, James Witek

Influenza Other Respir Viruses· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact Questionnaire.
Ann R Falsey, Edward E Walsh, Richard H Osborne, Yannick Vandendijck, Xiaohui Ren, James Witek

Influenza Other Respir Viruses· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults-A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study).
Ann R Falsey, Edward E Walsh, Stacey House, Yannick Vandenijck, Xiaohui Ren, James Witek

Open Forum Infect Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.
Clara Tmm de Kanter, Maria Buti, Ralph DeMasi, Sivi Ouwerkerk-Mahadevan, Anton Sm Dofferhoff, James Witek

Antivir Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Xavier Forns, Samuel Didier, David Mutimer, Stefano Fagiuoli, Miquel Navasa, James Witek

Ann Hepatol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
Gianpiero D'Offizi, Calogero Cammà, Chiara Taibi, Michael Schlag, Karin Weber, James Witek

New Microbiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric M Yoshida, Franco Felizarta, James Witek

Hepatology· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Paul Kwo, Norman Gitlin, Ronald Nahass, David Bernstein, Kyle Etzkorn, James Witek

Hepatology· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
Lai Wei, Tao Han, Dongliang Yang, Jeong Heo, Jia Shang, James Witek

J Gastroenterol Hepatol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin.
Bart Fevery, Kim Thys, Veerle Van Eygen, Thierry Verbinnen, Elizabeth Van Rossem, James Witek

Open Forum Infect Dis· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis.
Marisa Montes, Mark Nelson, Pierre Marie Girard, Joe Sasadeusz, Andrzej Horban, James Witek

J Int AIDS Soc· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Maria Luisa Montes, Mark Nelson, Pierre-Marie Girard, Joe Sasadeusz, Andrzej Horban, James Witek

J Antimicrob Chemother· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment.
Sivi Ouwerkerk-Mahadevan, Atef Halabi, Blanka Cieslarová, Indra Aerts, James Witek

J Clin Pharmacol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
Simone Susser, Mathieu Flinders, Henk W Reesink, Stefan Zeuzem, Glenn Lawyer, James Witek

Antimicrob Agents Chemother· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.
Christoph Sarrazin, Erkki Lathouwers, Monika Peeters, Bjorn Daems, Annemie Buelens, James Witek

Antiviral Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
Christoph Sarrazin, Inge Dierynck, Gavin Cloherty, Anne Ghys, Katrien Janssen, James Witek

J Clin Microbiol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.
Stefan Zeuzem, Ralph DeMasi, Alessandra Baldini, Bruce Coate, Donghan Luo, James Witek

J Hepatol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
Thomas N Kakuda, Lorant Leopold, Steven Nijs, Ann Vandevoorde, Herta M Crauwels, James Witek

J Clin Pharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Maria Buti, Kosh Agarwal, Yves Horsmans, William Sievert, Ewa Janczewska, James Witek

Gastroenterology· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
Zobair Younossi, Francesco Negro, Lawrence Serfaty, Stanislas Pol, Moises Diago, James Witek

Hepatology· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction between telaprevir and methadone.
Rolf van Heeswijk, Peter Verboven, Ann Vandevoorde, Petra Vinck, Jan Snoeys, James Witek

Antimicrob Agents Chemother· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
Monika Schöller-Gyüre, Thomas N Kakuda, James Witek, Sophie H Akuma, Goedele De Smedt

J Clin Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Thomas N Kakuda, Rodica Van Solingen-Ristea, Fatima Aharchi, Goedele De Smedt, James Witek

J Clin Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis